Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2017 | Exploiting signalling pathways involved in CLL to develop novel therapies

Silvia Deaglio • 11 Aug 2017
iwCLL 2017
Chronic Lymphocytic Leukemia

Silvia Deaglio, MD, PhD, from University of Turin, Turin, Italy, discusses current drugs on the market for the treatment of chronic lymphocytic leukemia (CLL), including anti-PD1/PDL1 antibodies and lenalidomide. She adds that there are several signalling pathways involved in CLL progression and these are under intense investigation by both pharmaceutical companies and academic researchers with the aim to develop drugs that could inhibit the tumour microenvironment. This video was recorded at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 in New York, NY.

More from Silvia Deaglio

1:33
Future advancements in the treatment of CLL
Silvia Deaglio • 31 Aug 2021
1:37
Utilizing the NOTCH1 pathway in the treatment of CLL
Silvia Deaglio • 31 Aug 2021
1:44
The molecular and microenvironmental basis of immunodysfunction in CLL
Silvia Deaglio • 31 Aug 2021
2:28
Utilizing the NOTCH1 pathway in CLL treatment
Silvia Deaglio • 21 Sep 2019

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
The content of VJHemOnc is intended for healthcare professionals